Welcome to our dedicated page for Scorpius Holdings SEC filings (Ticker: SCPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scorpius Holdings, Inc. (SCPX) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures, giving investors and analysts direct access to official information about its operations, financing activities, and risks. As a biotechnology-sector CDMO focused on biologic and cell therapy programs, Scorpius uses its SEC filings to report on revenue from contract services and grants, operating expenses, cash position, and material agreements that affect its financial condition.
Core documents such as the annual report on Form 10-K and quarterly reports on Form 10-Q provide detailed discussions of contract revenue, grant revenue, cost of revenues tied to biomanufacturing, and selling, general, and administrative expenses. Scorpius has disclosed that its audited financial statements include an explanatory paragraph regarding its ability to continue as a going concern, reflecting recurring losses from operations and limited revenue and cash flows. These filings are important for understanding the company’s liquidity, capital needs, and risk profile.
Scorpius also files numerous Current Reports on Form 8-K describing material definitive agreements and direct financial obligations. Recent 8-Ks detail non-convertible promissory notes issued to institutional investors, including principal amounts, interest rates, maturity dates, premium payments, and events of default such as cross-default provisions related to other indebtedness. Other 8-K filings cover matters like notices from NYSE American regarding delisting proceedings and noncompliance with timely filing requirements.
On Stock Titan, these SEC filings are updated in real time from EDGAR and paired with AI-powered summaries that explain key terms and implications in plain language. Users can quickly see what each 10-K, 10-Q, or 8-K means for Scorpius’ CDMO business, capital structure, and listing status without reading every page. The platform also makes it easier to track patterns in financing arrangements, going concern disclosures, and other recurring themes across filings.
Scorpius Holdings, Inc. entered into a series of four short-term, non-convertible promissory notes with an institutional investor, totaling approximately
Each note bears interest at
The notes were sold as unregistered securities in private transactions relying on exemptions under Section 4(a)(2) of the Securities Act and Regulation D, creating new direct financial obligations for the company.
Scorpius Holdings, Inc. reports a steep contraction in its CDMO business and severe financial stress for the quarter ended June 30, 2025. Revenue fell to $227,534 from $759,944 a year earlier, while the six‑month total dropped to $439,798 from $4.27 million, reflecting loss of major customers. The company posted a six‑month net loss attributable to Scorpius of $14.8 million and an accumulated deficit of $302.0 million.
Balance sheet pressure is acute: cash and cash equivalents were only $520,518, total liabilities were $29.5 million, and stockholders’ equity swung to a $(7.9) million deficit. Scorpius is in default on its December 2024 secured convertible notes and 2025 non‑convertible promissory notes, both held by related and institutional investors, and management concludes there is substantial doubt about its ability to continue as a going concern.
After quarter‑end, secured lenders conducted a UCC foreclosure sale of assets securing the December 2024 notes, closing on the sale of key CDMO facility assets for $16.25 million. The company states that, following this sale, it has no or nominal operations and assets. Separately, its common stock was delisted from NYSE American and now trades on the OTC Markets Pink tier, though Scorpius remains an SEC‑reporting company.
Scorpius Holdings (NASDAQ:SCPX) filed an 8-K reporting that on June 18, 2025 it entered into a short-term financing arrangement via a $130,000 non-convertible promissory note (the “Note”) with an institutional investor.
The Note carries 5.0% annual interest and becomes due on the earliest of: (i) July 31, 2025; (ii) completion of a defined corporate event; or (iii) an event of default. Default events include failure by the company or its subsidiaries to pay indebtedness exceeding $150,000 or default on any other outstanding notes. Should Scorpius complete a subsequent financing while the Note is outstanding, the holder may, at its discretion, require redemption of the full outstanding balance—up to 100% of the gross proceeds of such financing.
The Note was issued under Section 4(a)(2) and/or Regulation D exemptions, meaning the securities are restricted and not registered with the SEC. The disclosure triggers three 8-K items: Item 1.01 (material definitive agreement), Item 2.03 (creation of a direct financial obligation), and Item 3.02 (unregistered sales of securities). A copy of the Note is filed as Exhibit 4.1.
No additional financial statements, risk factors or legal proceedings were included. The filing principally signals a near-term liquidity action and introduces customary covenants that could accelerate repayment if certain events occur.
FAQ
What is the current stock price of Scorpius Holdings (SCPX)?
What is the market cap of Scorpius Holdings (SCPX)?
